Comparative Pharmacology
Head-to-head clinical analysis: PROKETAZINE versus STELAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROKETAZINE versus STELAZINE.
PROKETAZINE vs STELAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.
Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.
25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.
Adults: 2-10 mg orally twice daily; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is 15-20 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is approximately 24-30 hours (up to 40 hours in chronic use). Clinical context: Steady-state is reached in 5-7 days; allows once- or twice-daily dosing.
Primarily renal excretion of metabolites; less than 1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 20% of total clearance.
Primarily renal (metabolites and unchanged drug; ~50% as metabolites); biliary/fecal excretion accounts for <20%.
Category C
Category C
Phenothiazine Antipsychotic
Phenothiazine Antipsychotic